top of page

Bioasis

Biotech Protocols

Coming Soon

Headquarters for T cell production: Thymus organ controls T cell production by creating Thymus peptides. T cells become exhausted when their mitochondrial battery fails.

Healthy T Cells kill infected cells. Those dying cells are absorbed and degraded into basic building blocks by M2 Macrophages. Autophagy redistributes those building blocks to healthy cells.

Immune Protocol

Coming Later

Senescent cells can release 150x more inflammation than normal cells called SASP. NK Cells are attracted by SASP to kill the senescent cell.

Those dying senescent cells are absorbed and degraded into basic building blocks by M2 Macrophages during efferocytosis.

Senolytic Protocol

Coming Later

Microplastics, fatty plaques, trans fats, and more are increasing the burden of scavenging lipid cores by phagocytotic macrophages.

By leveraging M2 macrophages and their surface receptors, we can accelerate efferocytosis and target foreign particles like microplastics or plaques to reduce overall plaque volume at a faster rate than statins.

Plaque Protocol

Coming Later

Vitamin K2 is known for its ability to target calcification in arteries. K2 actually achieves this through a protein called MGP.

Matrix Gla-Protein (MGP) can be fragmented into peptides that can reduce the development of calcification.

Calcification Protocol

Coming Later

Valvular dysfunction and ventricle hypertrophy are common forms of cardiac degeneration that happen during aging.

By removing fibrotic scars while regenerating healthy collagens, we may be able to restabilize the elasticity of valves and ventricles while minimizing hypertrophy and valvular prolapse.

Myocardial Protocol

Coming Later

Many diseases from MS to ALS and Alzheimer's are caused by neurodegeneration in different areas of the brain.

Removing plaques, glial scars, and calcification while restoring stem cell supply with neurogenic growth factors may pave a path to restoring brain functionality.

Neurogenesis Protocol

Metrics

International Cost Burden:

100T+ Dollars

Estimated Cost Of Antibiotic Resistance By Year 2150

150M+ People

Deaths Per Decade From
Sepsis and Infections

20T+ Dollars

Cost Of COVID-19 Pandemic
On Global Economy

200M+ People

Deaths Per Decade From
Plaques and Heart Disease 

Humanitarian-Bioasis.png

Open-Source
Publications

The non-profit biotech arm is entirely open-source and follows the NIH-grant/university system (e.g. Stanford, Harvard):
 

  • Open-Source: Federal law ensures all results are published openly, making bio-tech discoveries accessible to all.

  • We fund bio-tech studies after the for-profit branch patents the formula, mirroring the NIH-grant model exhibited in universities across the globe today.


Humanitarian Impact: We deliver medicines licensed by the for-profit arm at fair market value, ensuring bio-tech benefits reach everyone.

Non-Profit Arm

Conducting mouse trials to assess effectiveness of patented compounds and peptide protocols.

Commercial Arm:

Patenting and licensing peptide protocols supported by the non-profit mouse trial data.

Licensing Patented
Biotech Protocols

The for-profit biotech arm patents the medical products that are licensed to the non-profit arm before clinical trials and product distribution: 

  • Drug design using physics-based molecular modelling software, pathway analysis, and synergistic mechanistic theories.

  • These R&D compounds are thoroughly analyzed, mechanistically explained, and patented before they are studied in combinations.


The molecular binding affinity to receptors and the known effects of those receptors provide a clear prediction of the molecule's effects in vivo.

Propsera.png

Phase One Clinical Trials

SENS Research Foundation.webp

Mice & Animal
Trials in U.S.A

API  Peptide
Manufacturer

Partnerships

Independent Purity Testing

bottom of page